Monge-Cadet Jeanne, Vairel Benjamin, Morisseau Mathilde, Moyal Elizabeth, Ducassou Anne, Chira Ciprian, Pagès Cécile, Sibaud Vincent, Brun Thomas, Modesto Anouchka
Radiation Oncology Department, Oncopole Claudius Regaud and Institut Universitaire du Cancer de Toulouse, 1 Avenue Irène Joliot-Curie, 31059 Toulouse, Cedex 9, France.
Surgery Department, Institut Universitaire du Cancer, 1 Avenue Irène Joliot-Curie, 31059 Toulouse, Cedex 9, France.
Cancers (Basel). 2024 Aug 1;16(15):2742. doi: 10.3390/cancers16152742.
While treatment of localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is based on surgery, brachytherapy, which delivers a high dose of radiation to tumor tissue while sparing healthy tissue, is an alternative. Since the withdrawal of iridium wires from the market, brachytherapy has mainly been performed with high-dose-rate iridium-192 (HDR). This study evaluated the efficacy of HDR brachytherapy in terms of local control, survival, toxicity, and quality of life in patients with facial periorificial cutaneous SCC or BCC treated in our center between 2015 and 2021. Sixty-seven patients were treated for SCC ( = 49) or BCC ( = 18), on the nose ( = 29), lip ( = 28), eyelid ( = 7), or ear ( = 3). The majority had Tis or T1 tumors (73.1%). After a median follow-up of 28 months, 8 patients had a local recurrence. The local control rate at 3 years was 87.05% (95% CI 74.6-93.7). All patients developed grade 1-2 acute radio-mucositis or radiodermatitis and one experienced reversible grade 3 acute radio-mucositis. Of the 27 patients who completed the quality-of-life questionnaire, 77.8% recommended the treatment. This study confirms that HDR brachytherapy for facial cutaneous carcinomas provides good local control, good tolerance, and satisfactory functional outcome.
虽然局部皮肤鳞状细胞癌（SCC）和基底细胞癌（BCC）的治疗以手术为主，但近距离放射治疗是一种替代方法，它能在保护健康组织的同时向肿瘤组织输送高剂量辐射。自从铱丝退出市场以来，近距离放射治疗主要采用高剂量率铱 - 192（HDR）进行。本研究评估了2015年至2021年在我们中心接受治疗的面部口周皮肤SCC或BCC患者中，HDR近距离放射治疗在局部控制、生存、毒性和生活质量方面的疗效。67例患者接受了SCC（n = 49）或BCC（n = 18）的治疗，病变位于鼻子（n = 29）、嘴唇（n = 28）、眼睑（n = 7）或耳朵（n = 3）。大多数患者患有Tis或T1期肿瘤（73.1%）。中位随访28个月后，8例患者出现局部复发。3年时的局部控制率为87.05%（95%CI 74.6 - 93.7）。所有患者均出现1 - 2级急性放射性粘膜炎或放射性皮炎，1例患者经历了可逆的3级急性放射性粘膜炎。在完成生活质量问卷的27例患者中，77.8%推荐该治疗方法。本研究证实，HDR近距离放射治疗面部皮肤癌可提供良好的局部控制、良好的耐受性和令人满意的功能结果。
